Other Income/Expenses (Net)

-$10.54M

TTM · Period ending: Jun 30, 2026 · USD

Latest reported-$10.54Mperiod endingJun 30, 2026

LCTX Other Income/Expenses (Net) ($700.00K → -$10.54M)

Annual Other Income/Expenses (Net)

High-resolution chart · PNG

LCTX other income/expenses (net) history

Annual fiscal periods · USD. Dates are reporting period ends; fiscal years can differ from calendar years.

Lineage Cell Therapeutics, Inc. Common Stock Other Income/Expenses (Net) — Annual fiscal periods (USD)
Period ending	Other Income/Expenses (Net) (USD)
Dec 31, 2025	-46,868,000
Dec 31, 2024	2,896,000
Dec 31, 2023	1,451,000
Dec 31, 2022	-3,292,000
Dec 31, 2021	5,941,000
Dec 31, 2020	4,523,000
Dec 31, 2019	19,642,000
Dec 31, 2018	-5,335,000
Dec 31, 2017	15,613,000
Dec 31, 2016	77,588,000
Dec 31, 2015	3,159,000
Dec 31, 2014	-472,137
Dec 31, 2013	-203,821
Dec 31, 2012	-305,183
Dec 31, 2011	212,821
Dec 31, 2010	-1,332,485
Dec 31, 2009	-1,624,233
Dec 31, 2008	-958,263
Dec 31, 2007	-215,853
Dec 31, 2006	-112,757
Dec 31, 2005	-55,840
Dec 31, 2004	-1,067,032
Dec 31, 2003	-134,716
Dec 31, 2002	-810,303
Dec 31, 2001	114,344
Dec 31, 2000	165,256
Dec 31, 1999	279,827
Dec 31, 1998	400,000
Jun 30, 1998	650,000
Jun 30, 1996	1,300,000
Jun 30, 1995	200,000
Jun 30, 1994	1,100,000
Jun 30, 1993	400,000
Jun 30, 1992	700,000